Data presented at the annual meeting of the American Society for Cancer Research suggest that a group of drugs called benzimidazoles may have activity in the treatment of advanced prostate cancer — at least in laboratory mice.
Chung et al. used three such drugs (fenbendazole, albendazole and mebendazole) to treat taxane-resistant tumors, and data suggest that the benzimidazoles limited tumor growth compared to treatment with paclitaxel. Whether such effects would be evident in men with advanced forms of prostate cancer is a very different question, however.
The benzimidazoles are drugs that have long been used to treat parasitic infections in man and animals. For example, albendazole has commonly been used in the treatment of certain types of tapeworm. They have well understood safety profiles and mechanisms of action when used as antiparasitic agents.
Additional information about this presentation is available in a report on MedPage Today.
Filed under: Drugs in development, Management | Tagged: activity, benzimidazole, mice |
THE "NEW" PROSTATE CANCER INFOLINK 
Leave a Reply